/
RNTX
$1.04+$0.07 (+7.08%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$83.1M
86M shares
52-week range
$0.86 – $2.18
13% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.19%
Moderate
Price (6 mo)
Loading chart…
Change$-0.89
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $1.0K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | −$1.0K |
| Gross margin | — | — | — | — | — | — |
| R&D | $11.2K | $17.0K | $18.0K | $4.0K | $14.2M | $11.0M |
| Operating income | −$20.5K | −$26.6K | −$27.6K | −$16.3K | −$65.1M | −$21.9M |
| EBITDA | −$20.3K | −$26.0K | −$27.2K | −$15.2K | −$28.0M | −$50.6M |
| Net income | −$21.2K | −$26.2K | −$27.3K | −$15.7K | −$62.9M | −$49.9M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.00 | -5.89 | -6.02 | -3.42 | -3.51 | -1.96 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $70M | $-0.53 | $-0.53–$-0.53 | 1 |
| 2027 | $128M | $-0.50 | $-0.50–$-0.50 | 1 |
| 2028 | $0 | $-0.66 | $-0.66–$-0.66 | 1 |
| 2029 | $0 | $-0.57 | $-0.57–$-0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Rein Therapeutics, Inc. Common Stock
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
www.reintx.com- Employees
- 10
- IPO / List date
- Jun 29, 2017
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds RNTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 24,500 | $31.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RNTX yet.
